Drug name - Latuda

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE45573 SUNOVION PHARMS INC Process for producing imide compound
Jun, 2025

(2 years from now)

CN1832946A SUNOVION PHARMS INC Method For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

CN100422178C SUNOVION PHARMS INC Method For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

IN235208B SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

IN200600349P4 SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

EP1652848A4 SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

EP1652848A1 SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

EP1652848B1 SUNOVION PHARMS INC Process For Producing Imide Compound
Jul, 2024

(1 year, 9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9815827 SUNOVION PHARMS INC Agent for treatment of schizophrenia Feb, 2024

(1 year, 4 months from now)

US9174975 SUNOVION PHARMS INC Remedy for integration dysfunction syndrome Feb, 2024

(1 year, 4 months from now)

US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome Aug, 2024

(1 year, 10 months from now)

USRE45573

(Pediatric)

SUNOVION PHARMS INC Process for producing imide compound Dec, 2025

(3 years from now)

US8729085 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US9555027 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US9907794 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US8883794 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US8883794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition Nov, 2026

(4 years from now)

US8729085

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition Nov, 2026

(4 years from now)

US9259423 SUNOVION PHARMS INC Method of treatment for mental disorders May, 2031

(8 years from now)

US9827242 SUNOVION PHARMS INC Method of treatment for mental disorders May, 2031

(8 years from now)

US9259423

(Pediatric)

SUNOVION PHARMS INC Method of treatment for mental disorders Nov, 2031

(9 years from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Treatment: Treatment of major depressive episodes associated with bipolar i disorder; treatment of schizophrenia; Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of schizophrenia; Treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder; Treatment of schizophrenia with improvement in attention function in schizophrenia; treatment of bipolar depression with improvement in attention function in bipolar disorder

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription
120MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.